Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 5:48 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1657–1680 of 3,553 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Fluids Clear all

Conditions: Stress Urinary Incontinence
Interventions: AMS 800 Artificial Urinary Sphincter; Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 145 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2024
U.S. locations: 16
States / cities: San Francisco, California • Aurora, Colorado • Iowa City, Iowa + 12 more

Conditions: Amputation Stumps, Pain
Interventions: Procedure/Surgery: Enriched Fat grafting; Procedure
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Dehydration
Interventions: Exercise Intervention; Other
Lead sponsor: Pennington Biomedical Research Center; Other
Eligibility: 18 Years to 35 Years · Male only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Obesity
Interventions: Cold exposure, Exposure to thermoneutral conditions; Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 21 Years to 65 Years · Female only
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Abuse Tobacco, Exposure
Interventions: Behavioral Intervention, Biospecimen Collection, Survey Administration; Behavioral · Other
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 21 Years to 29 Years
Enrollment: 158 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Surgical Incision
Interventions: Dermabond Prineo Skin Closure System, silk, 3M Steri-Strip; Device
Lead sponsor: Mehrdad Mark Mofid; Other
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Congenital Heart Disease (CHD)
Interventions: 2 mL SunButyrate-TG, Placebo, 4 mL SunButyrate-TG; Drug
Lead sponsor: University of Nebraska; Other
Eligibility: 1 Month to 3 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Urinary Stones
Interventions: Fluid prescription, Financial incentive, Structured Problem Solving; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 12 Years and older
Enrollment: 1,658 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 8
States / cities: Rochester, Minnesota • St Louis, Missouri • Cleveland, Ohio + 3 more

Conditions: Acute Lymphoblastic Leukemia
Interventions: Metformin, Vincristine, Dexamethasone, PEG-asparaginase, Doxorubicin, Intrathecal chemotherapy; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 1 Year to 30 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 5
States / cities: Miami, Florida • Orlando, Florida • St. Petersburg, Florida + 2 more

Conditions: Pain, Postoperative, Scoliosis Idiopathic
Interventions: Gabapentin, Placebo; Drug · Other
Lead sponsor: Emory University; Other
Eligibility: 10 Years to 18 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasm
Interventions: Total-Body Irradiation, Thiotepa, Fludarabine, Tacrolimus, Allogeneic CD34+-enriched and CD45RA-depleted PBSCs, Methotrexate, Cyclophosphamide, Peripheral Blood Stem Cell, Cyclosporine, Sirolimus, Busulfan, Bone Marrow Aspiration and Biopsy, Echocardiography, Multigated Acquisition Scan, Biospecimen Collection; Radiation · Drug · Biological + 1 more
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 1 Year to 60 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2030
U.S. locations: 3
States / cities: Tampa, Florida • Pittsburgh, Pennsylvania • Seattle, Washington

Conditions: Length of Labor, Second Stage of Labor, Intravenous Hydration of Labor
Interventions: Dextrose, Normal Saline; Other
Lead sponsor: MemorialCare Health System; Other
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Long Beach, California

Conditions: Eczema, Dermatitis, Skin Diseases, Genetic, Dermatitis, Atopic, Skin Diseases
Interventions: Trimethoprim/sulfamethoxazole (TMP/SMZ), Cephalexin, Doxycycline, Sodium hypochlorite, Placebo capsules, Placebo Sodium hypochlorite; Drug · Other
Lead sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); NIH
Eligibility: 2 Years to 50 Years
Enrollment: 130 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Charcot-Marie-Tooth Disease, Type IA
Interventions: PXT3003; Drug
Lead sponsor: Pharnext S.C.A.; Other
Eligibility: 17 Years to 67 Years
Enrollment: 187 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 9
States / cities: Los Angeles, California • Gainesville, Florida • Kansas City, Kansas + 6 more

Conditions: Bioavailability of Solifenacin Succinate, Pharmacokinetics of Solifenacin Succinate, Healthy Volunteers
Interventions: solifenacin succinate suspension, solifenacin succinate tablet; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: West Bend, Wisconsin

Conditions: Ear Infection, Middle Ear Infection, Otitis Media
Interventions: The OtoSight Middle Ear Scope; Device
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 6 Months to 12 Years
Enrollment: 165 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Cerebrospinal Fluid Shunts, Ventriculoperitoneal Shunt
Interventions: Ceftaroline; Drug
Lead sponsor: Basim Asmar; Other
Eligibility: 6 Months to 17 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Sample Collection; Other
Lead sponsor: Loma Linda University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: Recurrent Pregnancy Loss, Unexplained Infertility
Interventions: Uterine ERA and microbiome testing, Oral antibiotics and vaginal probiotics; Diagnostic Test · Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Sunnyvale, California

Conditions: Relapsed Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma
Interventions: Loncastuximab tesirine, Venetoclax; Drug
Lead sponsor: Paolo Caimi, MD; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Arteriovenous Dural Fistula
Interventions: PHIL® Liquid Embolic System; Device
Lead sponsor: Microvention-Terumo, Inc.; Industry
Eligibility: 22 Years to 80 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Albany, New York

Conditions: Postoperative Complications
Interventions: Not listed
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Orange, California

Conditions: Chronic Heart Failure, CKD Stage 3
Interventions: AquaPass System; Device
Lead sponsor: AquaPass Medical Ltd.; Industry
Eligibility: 21 Years to 79 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 8
States / cities: La Jolla, California • San Francisco, California • Minneapolis, Minnesota + 5 more

Conditions: Pleural Effusion, Malignant
Interventions: Standard Drainage Instructions, Aggressive Drainage Instructions; Other
Lead sponsor: Duke University; Other
Eligibility: 19 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 6
States / cities: Denver, Colorado • Baltimore, Maryland • Boston, Massachusetts + 3 more

Search by objective public record fields.

Artificial Urinary Sphincter Clinical Outcomes

Enriched Autologous Fat Grafting for Treating Pain at Amputation Sites

Fluid Balance During Exercise in the Heat With Water, Flavored Placebo, or a Carbohydrate-electrolyte Beverage Intake (The APEX Study)

The Role of Brown Adipose Tissue in Triglyceride Clearance in People

Perceptions of E-Cigarettes and Synthetic Cooling Agents, The ICE Study

Silk Scaffold Surgical Incision Dressing

Butyric Acid Supplementation for Gut Improvement After Cardiac Surgery in Kids

Prevention of Urinary Stones With Hydration

Vincristine, Dexamethasone, Doxorubicin, and PEG-asparaginase (VPLD) and Metformin for Relapsed Childhood Acute Lymphoblastic Leukemia (ALL)

Gabapentin and Chronic Post Surgical Pain

Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)

Effects of Rate and/or Presence of Dextrose on the Labor Course of Nulliparas

Effects of Treatments on Atopic Dermatitis

Assessing Long Term Safety and Tolerability of PXT3003 in Patients With Charcot-Marie-Tooth Disease Type 1A

Relative Bioavailability Study of Solifenacin Succinate Liquid Suspension (Fed and Fasting) Versus VESIcare Tablet (Fasting) in Healthy Volunteers

Diagnostic Utility of Otosight Middle Ear Scope

Ceftaroline Diffusion Into Cerebrospinal Fluid of Children

Biomarkers in Different Types of Amyotrophic Lateral Sclerosis (ALS) Patients Being Treated With Edaravone

Assessing the Endometrial Environment in Recurrent Pregnancy Loss and Unexplained Infertility

Loncastuximab Tesirine and Venetoclax for Relapsed/ Refractory Non-Hodgkin Lymphoma

PHIL in the Treatment of Intracranial dAVF.

Evaluation of Goal-Directed Intraoperative Hemodynamic Optimization Protocol

Reducing Fluid Overload in Heart Failure Patients Using a Non-invasive, Renal Independent System

Impact of Aggressive Versus Standard Drainage Regimen Using a Long Term Indwelling Pleural Catheter